Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
Metabolites · 06.05.2024 · 14 (5) · 264
DOI: 10.3390/metabo14050264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 06.05.2024. Verfasst von Carmela Morace und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
An acute metabolic complication of diabetes mellitus, especially type 1, is diabetic ketoacidosis (DKA), which is due to an increase in blood ketone concentrations. Sodium/glucose co-transporter-2 inhibitor (SGLT2-i) drugs have been associated with the occurrence of a particular type of DKA defined as euglycemic (euDKA), characterized by glycemic levels below 300 mg/dL. A fair number of euDKA cases in SGLT2-i-treated patients have been described, especially in the last few years when there has been a significant increased use of these drugs. This form of euDKA is particularly insidious because of its latent onset, associated with unspecific symptomatology, until it evolves (progressing) to severe systemic forms. In addition, its atypical presentation can delay diagnosis and treatment. However, the risk of euDKA associated with SGLT2-i drugs remains relatively low, but it is essential to promptly diagnose and manage it to prevent its serious life-threatening complications. In this narrative review, we intended to gather current research evidence on SGLT2i-associated euDKA from randomized controlled trials and real-world evidence studies, its diagnostic criteria and precipitating factors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
- Lipid Clinic and Cardiometabolic Disease Center, University Hospital of Messina, 98124 Messina, Italy.
- Internal Medicine and Diabetology Unit, University Hospital of Messina, 98124 Messina, Italy.
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", University of Messina, 98125 Messina, Italy.
ORCID-Profile: Federica Bellone, Giuseppe Mandraffino, Giovanni Squadrito, Herbert Ryan Marini
Zitieren
APA
Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., Russo, G. T., & Marini, H. R. (2024). Ketoacidosis and SGLT2 Inhibitors: A Narrative Review. Metabolites, 14(5), 264. https://doi.org/10.3390/metabo14050264
Vancouver
Morace C, Lorello G, Bellone F, Quartarone C, Ruggeri D, Giandalia A, et al. Ketoacidosis and SGLT2 Inhibitors: A Narrative Review. Metabolites. 2024;14(5):264. doi:10.3390/metabo14050264
BibTeX
@article{Morace2024,
author = {Morace, Carmela and Lorello, Giuseppe and Bellone, Federica and Quartarone, Cristina and Ruggeri, Domenica and Giandalia, Annalisa and Mandraffino, Giuseppe and Minutoli, Letteria and Squadrito, Giovanni and Russo, Giuseppina T and Marini, Herbert Ryan},
title = {Ketoacidosis and SGLT2 Inhibitors: A Narrative Review},
journal = {Metabolites},
year = {2024},
volume = {14},
number = {5},
pages = {264},
doi = {10.3390/metabo14050264}
}
EUVIMED